Skip to main content

Peer Review reports

From: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

Original Submission
1 Jul 2009 Submitted Original manuscript
27 Aug 2009 Reviewed Reviewer Report - John Cole
22 Sep 2009 Reviewed Reviewer Report - Hung Khong
31 Oct 2009 Author responded Author comments - Filippo Montemurro
Resubmission - Version 2
31 Oct 2009 Submitted Manuscript version 2
1 Nov 2009 Author responded Author comments - Filippo Montemurro
Resubmission - Version 3
1 Nov 2009 Submitted Manuscript version 3
10 Nov 2009 Reviewed Reviewer Report - Thomas Butler
22 Dec 2009 Reviewed Reviewer Report - John Cole
22 Dec 2009 Reviewed Reviewer Report - Hung Khong
23 Dec 2009 Author responded Author comments - Filippo Montemurro
Resubmission - Version 4
23 Dec 2009 Submitted Manuscript version 4
28 Jan 2010 Author responded Author comments - Filippo Montemurro
Resubmission - Version 5
28 Jan 2010 Submitted Manuscript version 5
Resubmission - Version 6
Submitted Manuscript version 6
29 Jan 2010 Author responded Author comments - Filippo Montemurro
Resubmission - Version 7
29 Jan 2010 Submitted Manuscript version 7
Publishing
1 Feb 2010 Editorially accepted
1 Feb 2010 Article published 10.1186/1471-2407-10-28

You can find further information about peer review here.

Back to article page